Chondroitin sulfate confirms its effectiveness in the control of synovitis in patients arthrosis.

At the Congress of the American College of Rheumatology, which brings together these days to 15,000 rheumatologists worldwide.

• The experts agree on the growing importance of treatment of synovitis (inflammation of the synovial membrane) as it is a major cause of pain and accelerating the course of osteoarthritis.

• Prof. P. Du Souich, moderator of the symposium "Synovitis and Osteoarthritis", presented as findings that treatment with Chondroitin sulfate relieves pain and can slow the development of osteoarthritis due to its ability to reduce synovitis.

• Also during the Congress has provided a meta-analysis, published this month in Current Medical Research and Opinion, which confirms that Chondroitin sulfate slows the progression of osteoarthritis of the course.

• The new evidence of the effect of Chondroitin Sulfate on synovitis are particularly important given that 50% of patients suffering from arthrosis this inflammation that causes pain and is the primary cause of disease progression.


Chondroitin sulfate treatment relieves pain and slows the development of osteoarthritis due to its ability to reduce inflammation of the synovial membrane, a condition that affected half of the patients arthrosis. These conclusions emerge from the data presented yesterday during the symposium "Osteoarthritis and Synovitis" that was held in San Francisco in the Congress of the American College of Rheumatology (ACR).

The growing importance of the inflammatory component of osteoarthritis is acquiring in recent times has led to Prof. Francis Berenbaum began yesterday symposium highlighting "the role it plays in the synovial membrane of degenerative arthritis" because, in osteoarthritis, synovitis (inflammation of the synovial membrane) produces pain and speeding up the process arthrosis.

The following interventions have been made known data reveal the capacity of Chondroitin Sulfate to act in the synovium and thus relieve pain and slow disease progression (DMOAD effect). Thus, Prof. M. Hochberg has shown the effect of symptomatic Chondroitin Sulfate with two very recent studies published in Osteoarthritis and cartilage and distinguished Annals of Rheumatic Diseases.

DMOAD regarding the effect of Chondroitin Sulfate, Prof. M. Hochberg has presented a major innovation: the "Meta-analysis of structure disease modifying effects of chondroitin sulfate in osteoarthritis." Published this month in the journal Current Medical Research and Opinion, this meta-analysis included 4 clinical trials on a total of 1088 patients with osteoarthritis of the knee and concluded that Chondroitin sulfate at a dose of 800 mg, reduces the loss of space intrarticular, with a statistically significant effect size.

Evidence on the effect DMOAD in addition to other previous studies, such as:

- Study STOPPED (accepted for publication in the journal of the ACR "Arthritis and Rheumatism).  Reginster JY, et al. A two-year prospective, randomized, double-blind, controlled study assessing the effect of chondroitin 4 & 6 sulfate (CS) on the structural progression of knee osteoarthritis: STOPPED (Study on Osteoarthritis Progression Prevention). Arthritis Rheum 2006 (Suppl), L42: 93.

- Study of Uebelhart D, Thon EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis cartilage 1998, 6 (Suppl A): 39-46.

- Study of Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis cartilage 2004; 12:269-76.

- Study of Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52: 779-86.

The symposium was also attended by experts such as Prof. P. du Souich, Prof. F. Berenbaum, Professor and Professor Moskowitz J.P. Pelletier. A complete program (1.5 credits for attendees to follow a continuing education program) that Bioiberica pharma research about condroprotección to rheumatologists around the world and ranks as the only Spanish company to participate in a symposium in the ACR within an educational program of osteoarthritis and synovitis.